Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA

Table 2 Comparison of patients’ demographic background in the remission and the non-remission groups by univariate analysis

Measurements	Remission group (n = 23)	Non-remission group (n = 20)	P-value
Age, year	39.2 ± 13.6	44.1 ± 16.2	ns
CAI score	8.9 ± 2.1	9.3 ± 2.3	ns
Duration of UC (year)	6.1 ± 7.3	8.6 ± 6.8	0.036
Interval between relapse and the 1^st GMA (day)	27.7 ± 31.0	76.2 ± 88.1	0.016
PSL at the 1^st GMA (mg/day)	18.7 ± 14.4	17.8 ± 10.5	ns
Cumulative PSL dose before 1st GMA (mg)	939.2 ± 1125.9	4578.5 ± 4752.6	0.006
WBC at the 1st GMA (/ul)	8304.1 ± 2432.3	9572.9 ± 2283.4	0.032
Hb at the 1^st GMA (g/dl)	12.0 ± 1.7	12.7 ± 2.0	ns
CRP at the 1^st GMA (mg/dl)	0.7 ± 1.0	0.7 ± 0.8	ns

CAI, clinical activity index; CRP, C-reactive protein; GMA, granulocyte and monocte apheresis; Hb, haemoglobin; WBC, white blood cell; ns, not significant (p > 0.05).

ISSN: 1471-230X